ML-SYS / 2026.07NON-CLINICAL RESEARCH MATERIALSORIGIN DECLARED BY LOT

← Compound index

RM-END / Endocrine and peptide-hormone analogs

Degarelix

Also known as: Firmagon · FE200486

Approved comparator exists

Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.

What this is

Degarelix is a synthetic decapeptide antagonist of the GnRH receptor. Antagonist and agonist analogs are indexed separately because their pharmacology and finished-product records differ.

Evidence position

The regulated injection record supports Grade A for the exact finished product.

What the record does not establish

The approval does not validate an unlabeled vial, a different salt, or an undeclared formulation.

Sources

  • 01
    Degarelix compound recordPubChem
    Shows
    Registry identity, structure, formula and synonyms for degarelix
    Does not show
    A registry record does not establish formulation, approval transfer or lot quality
  • 02
    Firmagon prescribing informationDailyMed / U.S. National Library of Medicine
    Shows
    U.S. label, formulation, regulated presentation and initial approval record
    Does not show
    Does not transfer approval or manufacturing controls to a research sample

External database index

LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE

Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.

PUBMED / FOUND RECORDS

  1. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.BJU international / 2008 DecPMID 19035858 / DOI 10.1111/j.1464-410X.2008.08183.x
  2. Degarelix. / 2012PMID 31643893
  3. Degarelix.Drugs / 2009 Oct 1PMID 19747011 / DOI 10.2165/10484080-000000000-00000
  4. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.European urology / 2023 JunPMID 36167599 / DOI 10.1016/j.eururo.2022.09.009
  5. Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research / 2023 May 15PMID 36862086 / DOI 10.1158/1078-0432.CCR-22-3350

CLINICALTRIALS.GOV / FOUND RECORDS

  1. Open-Label, Randomised Parallel-Group StudyWITHDRAWN / PHASE3 / Ferring PharmaceuticalsNCT00728533 / DIRECT intervention MATCH: Degarelix
  2. Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)ACTIVE_NOT_RECRUITING / PHASE1, PHASE2 / Mark SteinNCT03689699 / DIRECT intervention MATCH: Degarelix
  3. Impact of Estradiol AddbackCOMPLETED / PHASE1 / Mayo ClinicNCT01862835 / DIRECT intervention MATCH: Degarelix
  4. Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed TumorsACTIVE_NOT_RECRUITING / PHASE2 / Xiao X. Wei, MDNCT04126070 / DIRECT intervention MATCH: Degarelix
  5. A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate CancerCOMPLETED / PHASE2 / Ferring PharmaceuticalsNCT00116779 / DIRECT intervention MATCH: Degarelix

Related compounds

RM-END

Cetrorelix

Read entry →
RM-END

Ganirelix

Read entry →
RM-END

Leuprolide

Read entry →